Checkpoint Agrees To Sun Pharma Buyout
Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...
Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and ...
Analysts expect Sun to continue to be more aggressive in chasing speciality assets, but a successful launch is necessary for ...
H.C. Wainwright downgraded Checkpoint Therapeutics (CKPT) to Neutral from Buy with a price target of $4.10, down from $20, following the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results